BTIG Reiterates Buy on Avalo Therapeutics, Maintains $40 Price Target
Avalo Therapeutics Inc -3.87%
Avalo Therapeutics Inc AVTX | 13.66 | -3.87% |
BTIG analyst Julian Harrison reiterates Avalo Therapeutics (NASDAQ:
AVTX) with a Buy and maintains $40 price target.
